These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 28615731)

  • 1. The role of IL-6 in host defence against infections: immunobiology and clinical implications.
    Rose-John S; Winthrop K; Calabrese L
    Nat Rev Rheumatol; 2017 Jul; 13(7):399-409. PubMed ID: 28615731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Tanaka T; Narazaki M; Ogata A; Kishimoto T
    Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biology and medical implications of interleukin-6.
    Tanaka T; Kishimoto T
    Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
    Ho LJ; Luo SF; Lai JH
    Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of the interleukin-6 receptor.
    Tanaka T; Narazaki M; Kishimoto T
    Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hitting a complex target: an update on interleukin-6 trans-signalling.
    Waetzig GH; Rose-John S
    Expert Opin Ther Targets; 2012 Feb; 16(2):225-36. PubMed ID: 22324903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
    Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
    Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition.
    Garbers C; Aparicio-Siegmund S; Rose-John S
    Curr Opin Immunol; 2015 Jun; 34():75-82. PubMed ID: 25749511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
    Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
    Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential.
    Zhu S; Qian Y
    Clin Sci (Lond); 2012 Jun; 122(11):487-511. PubMed ID: 22324470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases.
    Ding C; Cicuttini F; Li J; Jones G
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1457-66. PubMed ID: 19715447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting gp130 to prevent inflammation and promote insulin action.
    Kraakman MJ; Allen TL; Whitham M; Iliades P; Kammoun HL; Estevez E; Lancaster GI; Febbraio MA
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():170-5. PubMed ID: 24003934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
    Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
    Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis.
    Kasama T; Isozaki T; Takahashi R; Miwa Y
    Int Immunopharmacol; 2016 Jun; 35():301-306. PubMed ID: 27085681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
    Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
    J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interleukin-6 From molecular mechanisms of signal transduction to physiological properties and therapeutic targeting].
    Drutskaya MS; Nosenko MA; Atretkhany KS; Efimov GA; Nedospasov SA
    Mol Biol (Mosk); 2015; 49(6):937-43. PubMed ID: 26710772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.